Answered You can buy a ready-made answer or pick a professional tutor to order an original one.
Assignment 1: Prescribing for Children and Adolescents Off-label prescribing is when a physician gives you a drug that the U.S. Food and Drug Administration (FDA) has approved to treat a condition dif
Assignment 1: Prescribing for Children and Adolescents
Off-label prescribing is when a physician gives you a drug that the U.S. Food and Drug Administration (FDA) has approved to treat a condition different than your condition. This practice is legal and common. In fact, one in five prescriptions written today are for off-label use.
—Agency for Healthcare Research and Quality
For this Assignment, you consider these questions and others as you explore FDA-approved (“on label”) pharmacological treatments, non-FDA-approved (“off-label”) pharmacological treatments, and nonpharmacological treatments for disorders in children and adolescents.
Reference:
Agency for Healthcare Research and Quality. (2015). Off-label drugs: What you need to know. https://www.ahrq.gov/patients-consumers/patient-involvement/off-label-drug-usage.html
To Prepare
- Your Instructor will assign a specific disorder for you to research for this Assignment.
- Use the Walden library to research evidence-based treatments for your assigned disorder in children and adolescents. You will need to recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating this disorder in children and adolescents.
The Assignment (1–2 pages)
- Recommend one FDA-approved drug, one off-label drug, and one nonpharmacological intervention for treating your assigned disorder in children and adolescents.
- Explain the risk assessment you would use to inform your treatment decision making. What are the risks and benefits of the FDA-approved medicine? What are the risks and benefits of the off-label drug?
- Explain whether clinical practice guidelines exist for this disorder and, if so, use them to justify your recommendations. If not, explain what information you would need to take into consideration.
- Support your reasoning with at least three scholarly resources, one each on the FDA-approved drug, the off-label, and a non-medication intervention for the disorder. Attach the PDFs of your sources. Use this topic to write it
- @
- 677 orders completed
- ANSWER
-
Tutor has posted answer for $20.00. See answer's preview
********** ** *********** for Children *** AdolescentsStudent **************************** one FDA-approved drug *** off-label **** *** *** ****************** ************ *** ******** **** ******** ******** in children *** adolescentsFDA-approved **** ***** * **** **** has been ********** cleared by *** Food and **** ************** ** ** **** and ********* for * specific ******* ** ********* **** ** *** ********** ******** ***** *** * ****** ***** than ******** ****** ** *** ******** label And * ****************** intervention ** * ********* **** **** *** ******* ***** There are **** reasons why a ***** ** ********** ***** ** ********** * ********** FDA-approved **** ********* drug ** ****************** intervention (Maher ***** ******** ***** ** some ***** the ************ use may *** ** *********** *** children ** *********** or *** off-label use *** ** **** *********** ** ***** cases * ****************** ************ may ** the **** ****** ****** important to talk ** **** child’s ********** ******** ***** *** * ********** ************ drug ********* **** or ****************** ************ ** being recommended *** ** make **** you ********** *** ***** *** ******************** ***** There *** **** FDA-approved ***** that can ** **** to ***** ********* in ******** and *********** **** ** ***** ***** *** approved *** ******** disorders ***** ****** *** ******** *** ******* *** ********* ****** ********* drug *** is common ** ******** *** adolescents ** some ***** the ********* *** *** ** more *********** **** the ************ *** ** other ***** *** ************ *** *** *** ** appropriate *** ******** ** *********** *** *** off-label *** may ** **** *********** ****************** interventions- ****************** ************* *** ********** **** ** *** ******* ***** ***** interventions *** ** used ***** ** ** combination with ***** ********** ********* FDA-approved drugs *** ********* ******************** ** * ******* ******* ****** ********* **** ** ************ for the ********* of ********* ******* ************* ******** ****** in ******** *** adolescents ** ***** ** ********** ****** ** ******** and ************** in *** brain ***** ***** ** improve focus and concentration Bupropion ** ** ************** that is *** ************ *** *** ********* ** ADHD ******* ** ** ***** **** ********* *** this purpose *** to *** ability to ******* ***** *** ************* Behavior therapy is * **** of ************* **** is designed ** **** ****** ******** ********* ** is often **** in the ********* ** **** ** ** *** **** ** ******* ***** *** concentration ******** ***** ***** ************ *** risk ********** *** would *** ** ****** **** ********* ******** ****** What *** *** ***** *** benefits ** *** ************ medicine? **** *** the ***** and ******** ** the off-label ********** *** **** ***** *** ******** ** consider **** ******** * treatment *** a child or ********** with * ******** (Furey ***** Wilkins ***** *** risks and benefits ** *** ************ medicine ********* **** *** ****************** ************ ****** ** ********* ********** ****** ****** * ******** **** ** *** ***** *** benefits to ******** include:a ************ **************** *** ************ ******** may not ** ********* in treating *** disorder- The FDA-approved ******** *** **** **** effects **** *** harmful to the ***** ** adolescentBenefits:- *** FDA-approved ******** *** **** proven to ** **** *** ********* ** ******** the ********* *** FDA-approved ******** is less ****** to ***** harm **** ** ********* drug or * ****************** ************* Off-label drug:Risks:- The ********* drug *** not be ********* in ******** *** ********* *** off-label **** *** **** **** effects **** *** ******* to *** ***** ** ******************** The ********* **** *** ** **** effective in ******** *** disorder **** *** ************ ********* *** ********* **** ** **** likely ** cause **** **** * ****************** ************* ****************** ******************** *** ****************** intervention *** not ** ********* in ******** the ********* The ****************** ************ *** **** **** ******* **** *** ******* to the ***** ** ******************** *** ****************** ************ ** **** likely to ***** **** than ** ************ ******** ** ** off-label ****** ******* ******* clinical ******** ********** exist *** **** disorder *** ** ** *** them ** justify **** recommendations If *** ******* **** information *** would need ** **** into ****************** are **** ******** ******** guidelines **** ***** *** disorders in children *** *********** ***** ********** can ** **** ** justify the *************** *** an ************ ******** off-label **** ** nonpharmacological ************ Some ** the *********** that ****** ** considered when making a ******** includes:1 *** ******** ** *** ********* The *** of *** ***** or *********** *** child ** adolescent’s ******* ******** *** child ** ************** ****** medical history5 *** ***** ** ************** response to ******** *********** The side ******* ** *** ************ medicine off-label drug ** nonpharmacological ************* *** ***** and ******** ** the ************ medicine off-label **** ** ****************** intervention8 *** ************ ** *** FDA-approved ******** ********* **** ** nonpharmacological ************* The **** of the ************ ******** off-label **** or ****************** *************************** * ***** ******* * ****** Prescribing **************** **** ****** * ********* ********* AMA ******* of ****** ***** ************** * * ***** ***** * * ****** A ******** overview of ********* use ** ************* drugs **** ******** medicine ****** ************ * * ***** ******** * ****** ******* ** *** *********** ************* review on ********* *** ** atypical antipsychotics ******* ** ******* **** ******** **** **** ** ****
